Is Valeant Cured of Headwinds? Analyst Sheds Light Following Meeting with Management

Valeant Pharmaceuticals (NYSE:VRX) management boiled down its position to BTIG analyst Tim Chiang, where the discussion gravitated on the standing of the company’s three leading segments: Bausch + Lamb/International, Branded Rx, and U.S. Diversified products. The biotech giant is not out of the woods, says Chiang after talking over the company’s bigger picture with the VRX team. However, does some growth potential remain for this comeback kid of the Street just yet?

Story Continues

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts